How do you interpret the findings from TroFuse-005 and, assuming future FDA approval, how would you incorporate sacituzumab tirumotecan (sac-TMT) into treatment options for previously treated advanced or recurrent endometrial cancer?

I think sac-TMT is likely a good option for patients progressing on immunotherapy maintenance. I wonder if it is best for biomarker-positive patients (TROP-2 intermediate or high expression) and not as good for patients with high-risk histologies (carcinosarcoma) and/or TROP-2–low expression. I must...